Evidence map›Paper›PMID 35062988›Full record

ArticleTrials2022

Comparison of Buyang Huanwu granules and Naoxintong capsules in the treatment of stable angina pectoris: rationale and design of a randomized, blinded, multicentre clinical trial.

Yu Wang, Yuhan Xu, Ling Zhang, Shuwei Huang, Liping Dou, Jiehong Yang, Wei Fu, Peng Zhou, Haitong Wan

Open access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Trials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Yu Wang *Department of Gastroenterology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Yuhan Xu *Institute of Cardio-cerebrovascular Disease, Zhejiang Chinese Medical University, Hangzhou, China.
Ling ZhangInstitute of Cardio-cerebrovascular Disease, Zhejiang Chinese Medical University, Hangzhou, China.
Shuwei HuangDepartment of Cardiology, First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.
Liping DouDepartment of Cardiology, Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.
Jiehong YangSchool of Basic Medical Sciences and Public Health, Zhejiang Chinese Medical University, Hangzhou, China.
Wei FuDepartment of Cardiac-Cerebral Diseases, Yinchuan Cardiac-Cerebral Treatment Internet Hospital, Yinchuan, China.
Peng ZhouInstitute of Brain and Heart CO Treatment, Zhejiang Chinese Medical University, Hangzhou, China.
Haitong WanInstitute of Cardio-cerebrovascular Disease, Zhejiang Chinese Medical University, Hangzhou, China. haitongw@163.com.
Zhejiang Chinese Medical University · CNYinchuan First People's Hospital · CNZhejiang University · CN

Funding

Key Technologies Research and Development Program 2019YFC1708600, 2019YFC17086003National Natural Science Foundation of China 81630105Zhejiang Provincial Program for the Cultivation of High-Level Innovative Health Talents 2019R51002
6 · The paper itself

Abstract

backgroundStable angina pectoris (SAP) currently seriously threatens the health of humans, and mortality is continuously rising. Current treatment strategies mainly include pharmaceutical therapy and revascularization. In China, Buyang Huanwu granules (BYHW) and Naoxintong capsules (NXT) have been used in the treatment of SAP, but it is not clear which agent is better in terms of relieving symptoms and improving quality of life. Therefore, we designed a clinical trial to compare the efficacy and safety of NXT and BYHW in the treatment of SAP.

methodsThis is a randomized, blinded, parallel controlled, multicentre clinical trial protocol. On the basis of standardized Western medicine treatment, a total of 128 SAP patients will be randomly divided into intervention group 1 (NXT group), intervention group 2 (BYHW group), and a control group (placebo group) at a 2:1:1 ratio. A 2-week run-in period is required prior to randomization, and a 1-week baseline period and 4-week treatment period are included in this study. The primary outcome is the efficacy rate of stable angina symptom score improvement; the secondary outcomes include the effect on electrocardiograms, Seattle Angina Questionnaire scores, and nitroglycerine consumption. DISCUSSION: This study will evaluate the efficacy and safety of NXT and BYHW in the treatment of SAP. The results will provide critical evidence for using Chinese herbal medicines to treat SAP.

trial registrationChinese Clinical Trials Registry ChiCTR1800015191. Registered on 13 March 2018. http://www.chictr.org.cn/showproj.aspx?proj=25818 . All the registration items can be found within the protocol.

Indexed as

Angina, StableDrugs, Chinese HerbalCapsulesHumansMulticenter Studies as TopicQuality of LifeRandomized Controlled Trials as TopicTreatment Outcomebuyang huanwuCapsulesDrugs, Chinese HerbalnaoxintongBuyang Huanwu granulesNaoxintong capsulesRandomized controlled trialStable angina pectorisTraditional Chinese medicine

Identifiers

PMID35062988
PMCPMC8780317
OpenAlexW4206932734

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.